Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05469113 · ClinicalTrials.gov registry record · Phase 1
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05469113 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT05469113, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.
Interventions
- DRUG Selpercatinib
- DRUG Repaglinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2019-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05469113
The ClinicalTrials.gov registry entry for NCT05469113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selpercatinib is the first listed.
NCT05469113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05469113 about?
NCT05469113 is a clinical study titled "A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants". The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 ...
What is the current status of trial NCT05469113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-01-29. Estimated completion is 2019-03-05.
What interventions are being tested in trial NCT05469113?
The interventions under investigation include: Selpercatinib (DRUG), Repaglinide (DRUG).
Who is sponsoring clinical trial NCT05469113?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.